DUBLIN, May 19, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Allergy Rhinitis Drugs Market 2017-2021" report to their offering.
The analysts forecast the global allergy rhinitis drugs market to grow at a CAGR of 3.05% during the period 2017-2021.
The report covers the present scenario and the growth prospects of the global allergy rhinitis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The report also includes a discussion of the key vendors operating in this market.
Allergic diseases are one of the fastest-growing chronic diseases globally. If not managed properly at an early stage, allergic diseases such as rhinitis can increase the risk of asthma in the later stage of life. Several organizations around the world work to better understand the pathogenesis of allergic diseases.
According to the report, one driver in the market is increasing awareness about allergic rhinitis. The increasing awareness about allergic rhinitis is fueling the market growth. Due to various environmental factors, the prevalence of allergic rhinitis is increasing in US. In the US, awareness programs and initiatives are undertaken by various organizations to spread disease awareness among the target population.
Further, the report states that one challenge in the market is patent expiries and generic competition. The patent expiry of major drugs approved for allergy rhinitis is expected to adversely affect the market and slow down its growth during the forecast period. The patent expiry of a drug often results in the loss of the exclusive market, leading to a rapid decline in sales.
- Meda Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Pipeline Landscape
Part 06: Market landscape
Part 07: Market segmentation by drug class
Part 08: Geographical segmentation
Part 09: Decision framework
Part 10: Drivers and challenges
Part 11: Market trends
Self-medication using OTC products
Part 12: Vendor Landscape
Part 13: Vendor landscape
Part 14: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/ns498x/global_allergy
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets